Flagship Pioneering has unveiled Foghorn Therapeutics, a unique life science innovation enterprise that uses its proprietary Gene Traffic Control product platform to discover and develop drugs based on novel insights into the chromatin regulatory system which directs gene expression in cells. Flagship Pioneering developed and launched Foghorn Therapeutics through its innovation foundry, Flagship VentureLabs, and […]

Researchers have identified a new ALS gene called KIF5A. This important gene discovery, funded by The ALS Association through Ice Bucket Challenge donations, will help researchers understand ALS disease pathways and represents a potential new ALS therapeutic target. This was a large collaborative effort involving over 250 researchers, led by John Landers, Ph.D., Professor of […]

Biogen has announced an agreement to acquire from Pfizer a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. The purchase will […]

Cambridge-based Rubius Therapeutics, a biotech company pioneering a new class of cellular therapies, today announced the successful completion of an oversubscribed $100 million crossover financing. In just under nine months, the company has now raised over $220 million. Rubius has developed the technology to grow, genetically engineer and mature long circulating Red Cell Therapeutics (RCT) […]